These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 15782278)

  • 21. Comparative efficacy of azithromycin versus clarithromycin in combination with beta-lactams to treat community-acquired pneumonia in hospitalized patients: a systematic review.
    Al-Salloum J; Gillani SW; Mahmood RK; Gulam SM
    J Int Med Res; 2021 Oct; 49(10):3000605211049943. PubMed ID: 34719987
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Are third-generation cephalosporins associated with a better prognosis than amoxicillin-clavulanate in patients hospitalized in the medical ward for community-onset pneumonia?
    Batard E; Javaudin F; Kervagoret E; Caruana E; Le Bastard Q; Chapelet G; Goffinet N; Montassier E
    Clin Microbiol Infect; 2018 Nov; 24(11):1171-1176. PubMed ID: 29964229
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Respiratory fluoroquinolone monotherapy vs. β-lactam plus macrolide combination therapy for hospitalized adults with community-acquired pneumonia: A systematic review and meta-analysis of randomized controlled trials.
    Choi SH; Cesar A; Snow TAC; Saleem N; Arulkumaran N; Singer M
    Int J Antimicrob Agents; 2023 Sep; 62(3):106905. PubMed ID: 37385561
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative Efficacy of Beta-Lactams and Macrolides in the Treatment of Pediatric Pneumonia: A Systematic Review.
    Al Saeedy D; Gillani SW; Al-Salloum J; Moosvi A; Eissa M; Gulam SM
    Curr Pediatr Rev; 2020; 16(4):307-313. PubMed ID: 32895041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monotherapy versus Combination Therapy in Patients Hospitalized with Community-Acquired Pneumonia.
    Kolditz M; Halank M; Höffken G
    Treat Respir Med; 2006; 5(6):371-83. PubMed ID: 17154666
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization.
    Querol-Ribelles JM; Tenías JM; Querol-Borrás JM; Labrador T; Nieto A; González-Granda D; Martínez I
    Int J Antimicrob Agents; 2005 Jan; 25(1):75-83. PubMed ID: 15620830
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of macrolide therapy on mortality of HIV-infected patients with community-acquired pneumonia in a tertiary teaching hospital.
    Mello CF; Negra MD
    Braz J Infect Dis; 2011; 15(3):262-7. PubMed ID: 21670928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: a US-based study.
    Frei CR; Jaso TC; Mortensen EM; Restrepo MI; Raut MK; Oramasionwu CU; Ruiz AD; Makos BR; Ruiz JL; Attridge RT; Mody SH; Fisher A; Schein JR
    Curr Med Res Opin; 2009 Apr; 25(4):859-68. PubMed ID: 19231913
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Coverage of atypical pathogens for hospitalised patients with community-acquired pneumonia is not guided by clinical parameters.
    Piso RJ; Arnold C; Bassetti S
    Swiss Med Wkly; 2013; 143():w13870. PubMed ID: 24089030
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of guideline-concordant antibiotics and macrolide/β-lactam combinations in 3203 patients hospitalized with pneumonia: prospective cohort study.
    Asadi L; Eurich DT; Gamble JM; Minhas-Sandhu JK; Marrie TJ; Majumdar SR
    Clin Microbiol Infect; 2013 Mar; 19(3):257-64. PubMed ID: 22404691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative randomized trial of azithromycin versus erythromycin and amoxicillin for treatment of community-acquired pneumonia in children.
    Kogan R; Martínez MA; Rubilar L; Payá E; Quevedo I; Puppo H; Girardi G; Castro-Rodriguez JA
    Pediatr Pulmonol; 2003 Feb; 35(2):91-8. PubMed ID: 12526069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mortality in patients with community-onset pneumonia at low risk of drug-resistant pathogens: Impact of β-lactam plus macrolide combination therapy.
    Okumura J; Shindo Y; Takahashi K; Sano M; Sugino Y; Yagi T; Taniguchi H; Saka H; Matsui S; Hasegawa Y;
    Respirology; 2018 May; 23(5):526-534. PubMed ID: 29239493
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Etiology and treatment of community-acquired pneumonia in ambulatory children.
    Wubbel L; Muniz L; Ahmed A; Trujillo M; Carubelli C; McCoig C; Abramo T; Leinonen M; McCracken GH
    Pediatr Infect Dis J; 1999 Feb; 18(2):98-104. PubMed ID: 10048679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Beta-lactam versus beta- lactam/macrolide therapy in pediatric outpatient pneumonia.
    Ambroggio L; Test M; Metlay JP; Graf TR; Blosky MA; Macaluso M; Shah SS
    Pediatr Pulmonol; 2016 May; 51(5):541-8. PubMed ID: 26367389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of two guideline-concordant antimicrobial combinations in elderly patients hospitalized with severe community-acquired pneumonia.
    Wilson BZ; Anzueto A; Restrepo MI; Pugh MJ; Mortensen EM
    Crit Care Med; 2012 Aug; 40(8):2310-4. PubMed ID: 22622401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy.
    Charles PG; Whitby M; Fuller AJ; Stirling R; Wright AA; Korman TM; Holmes PW; Christiansen KJ; Waterer GW; Pierce RJ; Mayall BC; Armstrong JG; Catton MG; Nimmo GR; Johnson B; Hooy M; Grayson ML;
    Clin Infect Dis; 2008 May; 46(10):1513-21. PubMed ID: 18419484
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ceftriaxone versus ceftriaxone plus a macrolide for community-acquired pneumonia in hospitalized patients with HIV/AIDS: a randomized controlled trial.
    Figueiredo-Mello C; Naucler P; Negra MD; Levin AS
    Clin Microbiol Infect; 2018 Feb; 24(2):146-151. PubMed ID: 28648859
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes of Macrolide Deescalation in Severe Community-acquired Pneumonia.
    Hopkins TM; Juang P; Weaver K; Kollef MH; Betthauser KD
    Clin Ther; 2019 Dec; 41(12):2540-2548. PubMed ID: 31676040
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Combined β-Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients With Community-Acquired Pneumonia.
    Ceccato A; Cilloniz C; Martin-Loeches I; Ranzani OT; Gabarrus A; Bueno L; Garcia-Vidal C; Ferrer M; Niederman MS; Torres A
    Chest; 2019 Apr; 155(4):795-804. PubMed ID: 30471269
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibiotic Therapy for Adults Hospitalized With Community-Acquired Pneumonia: A Systematic Review.
    Lee JS; Giesler DL; Gellad WF; Fine MJ
    JAMA; 2016 Feb; 315(6):593-602. PubMed ID: 26864413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.